Publications by authors named "David T Valenta"

Claim this Profile
A
Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization.
Shannon L Werner, Ryon P Graf, Mark Landers, David T Valenta, Matthew Schroeder

J Circ Biomark· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Derek Ostertag, Karin K Amundson, Fernando Lopez Espinoza, Bryan Martin, Taylor Buckley, David T Valenta

Neuro Oncol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polymer particle shape independently influences binding and internalization by macrophages.
Gaurav Sharma, David T Valenta, Yoav Altman, Sheryl Harvey, Hui Xie

J Control Release· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TARGETING OF MACROPHAGE FOAM CELLS IN ATHEROSCLEROTIC PLAQUE USING OLIGONUCLEOTIDE-FUNCTIONALIZED NANOPARTICLES.
Gaurav Sharma, Zhi-Gang She, David T Valenta, William B Stallcup, Jeffrey W Smith

Nano Life· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Macrophage PLTP is atheroprotective in LDLr-deficient mice with systemic PLTP deficiency.
David T Valenta, Joshua J Bulgrien, David J Bonnet, Linda K Curtiss

J Lipid Res· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overexpression of human ApoAI transgene provides long-term atheroprotection in LDL receptor-deficient mice.
David T Valenta, Joshua J Bulgrien, Carole L Banka, Linda K Curtiss

Atherosclerosis· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atheroprotective potential of macrophage-derived phospholipid transfer protein in low-density lipoprotein receptor-deficient mice is overcome by apolipoprotein AI overexpression.
David T Valenta, Nicolas Ogier, Gary Bradshaw, Audrey S Black, David J Bonnet

Arterioscler Thromb Vasc Biol· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What is so special about apolipoprotein AI in reverse cholesterol transport?
Linda K Curtiss, David T Valenta, Neil J Hime, Kerry-Anne Rye

Arterioscler Thromb Vasc Biol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis